- Home
- DLB vs HALO Comparison
DLB vs HALO Comparison
Compare DLB & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLB
- HALO
- Stock Information
- Founded
- DLB 1965
- HALO 1998
- Country
- DLB United States
- HALO United States
- Employees
- DLB N/A
- HALO N/A
- Industry
- DLB Multi-Sector Companies
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DLB Miscellaneous
- HALO Health Care
- Exchange
- DLB Nasdaq
- HALO Nasdaq
- Market Cap
- DLB 7.9B
- HALO 7.4B
- IPO Year
- DLB 2005
- HALO N/A
- Fundamental
- Price
- DLB $76.62
- HALO $53.68
- Analyst Decision
- DLB Strong Buy
- HALO Buy
- Analyst Count
- DLB 4
- HALO 9
- Target Price
- DLB $101.75
- HALO $63.56
- AVG Volume (30 Days)
- DLB 400.0K
- HALO 3.1M
- Earning Date
- DLB 05-01-2025
- HALO 05-06-2025
- Dividend Yield
- DLB 1.71%
- HALO N/A
- EPS Growth
- DLB 36.08
- HALO 55.40
- EPS
- DLB 2.64
- HALO 3.76
- Revenue
- DLB $1,320,184,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- DLB $6.38
- HALO $24.79
- Revenue Next Year
- DLB $4.65
- HALO $22.65
- P/E Ratio
- DLB $29.29
- HALO $13.83
- Revenue Growth
- DLB 4.03
- HALO 25.64
- 52 Week Low
- DLB $66.35
- HALO $41.28
- 52 Week High
- DLB $89.66
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- DLB 50.04
- HALO 41.37
- Support Level
- DLB $76.69
- HALO $47.50
- Resistance Level
- DLB $77.59
- HALO $53.95
- Average True Range (ATR)
- DLB 1.19
- HALO 3.31
- MACD
- DLB 0.23
- HALO -0.96
- Stochastic Oscillator
- DLB 64.84
- HALO 23.10
About DLB Dolby Laboratories
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company designs and manufactures audio, imaging, accessibility, and other hardware and software solutions for the cinema, with occasional applications in the television, broadcast, and live entertainment industries. The company operates in the United States and internationally.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.